GlaxoSmithKline Pharmaceuticals Limited has announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The company reported its revenue from operations, profit before tax, and net profit for the respective periods. The Board of Directors also approved the appointment of new statutory auditors and changes in senior management during a meeting held on November 3, 2026.
GlaxoSmithKline Pharmaceuticals Announces Q2 2026 Financial Performance
GlaxoSmithKline Pharmaceuticals Limited (GSK) has disclosed its unaudited financial results for the second quarter and the six-month period ended September 30, 2026. The company’s Board of Directors convened on November 3, 2026, to approve these results, which include both standalone and consolidated figures.
Key Financial Highlights
For the quarter ended September 30, 2026, GSK reported total income of ₹125,268 Lakhs on a standalone basis, with a profit for the period of ₹33,462 Lakhs. On a consolidated basis, total income stood at ₹125,635 Lakhs, resulting in a profit for the period of ₹33,588 Lakhs.
The six-month period ended September 30, 2026, saw standalone total income of ₹223,873 Lakhs and a profit of ₹58,795 Lakhs. Consolidated figures for the same period showed total income of ₹223,855 Lakhs and a profit of ₹57,306 Lakhs.
Changes in Management and Auditing
In addition to the financial results, the Board approved the appointment of Mr. Sandeep Seth as Head – Ethics & Compliance, effective from November 3, 2026. Furthermore, M/s. Walker Chandiok & Co LLP were appointed as the Statutory Auditors of the Company for a five-year term commencing from the financial year 2027-28, subject to shareholder approval.
Auditor’s Review
The financial results have undergone a limited review by the statutory auditors. Deloitte Haskins & Sells LLP provided a review report on the interim consolidated and standalone financial results, concluding that based on their review, nothing has come to their attention to suggest any material misstatement.
Source: BSE
